Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

66 results about "Anti-agents" patented technology

Efficient flame-retardant film and production process thereof

The invention provides an efficient flame-retardant film and a production process thereof, and relates to the technical field of flame-retardant films. An efficient flame-retardant film comprises a surface layer, a core layer and an inner layer. The surface layer is prepared from the following raw materials in parts by mass: 10 to 40 parts of copolymerized PP, 7 to 36 parts of a flame retardant, 0.4 to 1.5 parts of an anti-UV agent, 0.01 to 0.1 part of an anti-aging agent, 0.5 to 3 parts of an anti-sticking agent and 0.2 to 3 parts of titanium dioxide master batch. The flame-retardant film provided by the invention has excellent flame retardance.
Owner:YUNYANG JINTIAN PLASTIC

Systems and methods for simulating coughs and sneezes

The present invention relates to pathogen cleaning and simulation of pathogen spreading. More particularly, some implementations of the described invention relate to systems and methods for spraying materials in a manner that mimics the spreading of pathogens from coughing or sneezing. Some implementations further relate to using a non-aerosol sprayer that produces both a mist and droplets of a mixture containing water, a fluorescent marker, a surfactant, and an antifoaming agent. In some cases, the pump sprayer defines an internal compartment that includes the mixture. In some cases, the sprayer further includes a pump mechanism that is configured to be pumped to compress a gas within the compartment and a release valve that is configured to release pressure within the compartment through a spray nozzle of the sprayer such that droplets and mist of the mixture are sprayed from the nozzle. Other implementations are also described.
Owner:DMA INT

Biomarkers for assessing the response status for treatment of inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients

The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with with anti-α4β7 agent may be useful in a human suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and / or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent.
Owner:OSE IMMUNOTHERAPEUTICS SA +1

Anti-UV anti-aging master batch for pesticide-resistant PE net and preparation method of anti-UV anti-aging master batch

The invention discloses an anti-UV and anti-aging master batch for a pesticide-resistant PE net and a preparation method of the anti-UV and anti-aging master batch, the master batch comprises the following components in percentage by mass: 70-80 wt% of matrix resin PE, 2-4 wt% of an anti-UV agent, 1-2 wt% of an antioxidant, 10-15 wt% of a pesticide-resistant agent and 5-12 wt% of an adjuvant, and the invention relates to the technical field of master batches for PE nets. Through scientific and reasonable proportioning, the anti-UV agent, the antioxidant, the pesticide-resistant agent and other additives have a synergistic effect, the pesticide resistance, ultraviolet resistance and aging resistance of the PE net are remarkably improved, uniform distribution of the additives in a PE matrix is guaranteed by using the dispersing agent and the plasticizer, and therefore the overall performance of the master batch is improved, and the service life of the PE net is prolonged. The master batch provided by the invention is suitable for production of various PE nets, and is especially suitable for agricultural protective nets which are used for a long time in high-pesticide and high-ultraviolet environments.
Owner:JUQI PLASTIC (LIAONING) CO LTD

Immunochromatography test strip and kit for rapidly detecting human urinary nuclear matrix protein 22

The invention discloses an immunochromatography test strip and a kit for rapidly detecting human urinary nuclear matrix protein 22, the test strip comprises a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad which are connected in sequence, the nitrocellulose membrane is provided with a detection line and a quality control line in sequence, the detection line is coated with an NMP22 antibody treated by a blocking agent, and the quality control line is coated with a quality control line. The quality control line is coated with a DNP antigen treated by a blocking agent, and the blocking agent comprises the following components in percentage by mass: 1% of an anti-heterotropism antibody agent, 0.2 mg / mL of an anti-rheumatoid factor agent, 1% of an anti-HAMA agent, 0.02 mol / L of PBS, 5% of sucrose and 0.1% of PC300. The immunochromatography test strip for rapidly detecting the human urinary nuclear matrix protein 22 is high in detection speed, capable of obtaining a detection result within 1-15 min, free of instruments, easy to operate, low in price, suitable for basic medical institutions and suitable for popularization and self-detection.
Owner:JIANGSU KANGPU BIOMEDICAL TECH CO LTD

Compositions and Methods for Treatment of Edema

Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-β1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade

Methods are provided for targeting cells for depletion, including without limitation tumor cells such as solid tumor cells, in a regimen comprising contacting the tumor and immune effector cells with an effective dose of an anti-MSDC agent that reduces the abundance, immunosuppressive activity, or tumor recruitment of CXCR2+ granulocytic-myeloid derived suppressor cells, for example, an inhibitor of CXCR2; in combination with an effective dose of an inhibitor of CD47 / SIRPα signaling.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Compounds with broad-spectrum antifungal activity and plant-induced resistance and methods of use

PendingCN122355834ABiotechnologyFungus Diseases
This invention provides compounds and methods of application that possess both broad-spectrum antifungal activity and plant-induced resistance, belonging to the field of agricultural technology. It addresses the problem that "traditional pure immune inducers must be applied before disease onset, making it difficult to meet the full-cycle control needs of disease prevention and treatment in the field." Compared to the previously developed PC1 and PC20, the two compounds of this invention, 2,4-dibromo-6-nitrophenol and 7-deazon-2'-deoxy-7-iodoadenosine, can both inhibit the growth of rice blast fungus and significantly improve rice resistance to rice blast through foliar spraying, meeting the full-cycle control needs of disease prevention and treatment in the field. Furthermore, these two compounds can directly inhibit the growth of various fungal pathogens such as peanut white mold, tomato gray mold, wheat scab, rice bakanae disease, rice false smut, mango malformation, and banana wilt.
Owner:SHANDONG ACADEMY OF AGRICULTURAL SCIENCES

Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same

Some embodiments relate to a sustained release silica hydrogel composite comprising an anti-complement agent and methods of using same to treat ophthalmological conditions. The anti-complement agent may be an anti-C5 agent comprising a C5-specific aptamer.
Owner:ASTELLAS US LLC

Application of 2-cyclohexenol in antibacterial, promoting plant growth, and / or inducing plant resistance

The present invention provides an application of 2-bornanol in antibacterial, promoting plant growth, and / or inducing plant resistance, and also provides a method for antibacterial, promoting plant growth, and / or inducing plant resistance, as well as a biological pesticide, a plant resistance inducer, and a plant growth regulator. The present invention directly clarifies the feasibility of 2-bornanol as a plant growth regulator, a resistance inducer, and a biological pesticide and is proven in field trials. Compared with other methods of biological pesticides and growth regulators, the application and method of the present invention have the advantages of simple operation, low requirements for outdoor spraying conditions, and can be popularized and applied in the field.
Owner:YUNNAN AGRICULTURAL UNIVERSITY

Methods and uses related to t cell therapy and production of same

Provided herein are uses of T cells, e.g., chimeric antigen receptor (CAR) T cells, for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma) wherein the subject being treated has previously received a topoisomerase inhibitor, a proteasome inhibitor, an anti-CD38 agent, an immunomodulatory agent, or an anti-SLAMF agent therapy.
Owner:CELGENE CORP

Methods and Compositions for Treatment of Angiogenic Disorders Using Anti-VEGF Agents

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.
Owner:RGT UNIV OF CALIFORNIA

Anti-TLR9 agents and compositions and methods for making and using the same

Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.
Owner:BIOLEGEND INC

Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same

To provide methods for treating diseases.SOLUTION: The present disclosure provides prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides, and compositions, methods and kits thereof. Such compounds can be useful for treating virus infections including human immunodeficiency virus. The compounds have the following formula (I). Provided herein are compounds functioning as antiviral agents (in some embodiments, as anti-HIV agents), pharmaceutical compositions comprising such a compound and optionally in combination with one or more (e.g., two, three or four) additional therapeutic agents, and methods for using such compounds and compositions. Embodiment of every disclosed compound includes pharmaceutically acceptable salts and stereoisomers thereof or a mixture of the stereoisomers.SELECTED DRAWING: None
Owner:GILEAD SCIENCES INC

Method for preventing and treating flue-cured tobacco virus disease

The present application discloses a method for preventing and treating flue-cured tobacco virus disease, belonging to the field of plant protection. The method comprises (1) prevention: applying agents during the seedling stage, before transplanting, after transplanting, and during the field stage of tobacco growth; during the seedling stage: applying guanidine-copper acetate before thinning, replanting, and weeding; applying amino oligosaccharides and antiviral microbial agents before sealing the trays; applying cinclostrobin acetate solution after sealing the trays and before cutting the leaves; applying ningnanmycin and amino oligosaccharides before and after transplanting; applying insecticides mixed with plant resistance inducers, antiviral microbial agents, trace elements, and foliar fertilizers from one week after transplanting the seedlings to the stage of clustering; (2) treatment of the disease. The method prevents flue-cured tobacco virus disease by applying antiviral agents early in the whole growth stage of tobacco; and combining the antiviral agents with other specific agents to improve tobacco plant resistance, reduce the incidence of viral diseases, and improve the cure rate of viral diseases.
Owner:SHANDONG WEIFANG TOBACCO CO LTD

Anti-TLR9 agents and compositions and methods for making and using the same

Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.
Owner:BIOLEGEND INC

Dosing regimen for Anti-BCMA agents

The present invention relates to the dosage and administration of anti-BCMA agents for the treatment of BCMA positive neoplasms. More specifically, the present invention relates to an antibody construct comprising a first domain which binds to BCMA, a second domain which binds to CD3 and a third domain which extends or enhances the half-life of the antibody construct, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle. Moreover, the invention relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified dose of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.
Owner:AMGEN RESEARCH (MUNICH) GMBH +1

Immunochromatographic test strip and kit for rapid detection of human urine nuclear matrix protein 22

The invention discloses an immunochromatographic test strip and a kit for rapid detection of human urine nuclear matrix protein 22, the test strip includes a sample pad, a conjugate pad, a nitrocellulose membrane and a water-absorbing pad connected in sequence, a detection line and a quality control line are sequentially arranged on the nitrocellulose membrane, the detection line is coated with a blocker-treated NMP22 antibody, the quality control line is coated with a blocker-treated DNP antigen, the blocker includes 1% anti-heterophilic antibody agent, 0.2mg / mL anti-rheumatoid factor agent, 1% anti-HAMA agent, 0.02mol / L PBS, 5% sucrose and 0.1% PC300, and the above percentages are mass percentages. The immunochromatographic test strip for rapid detection of human urine nuclear matrix protein 22 of the present invention has a fast detection speed, and the test result is obtained in 1-15min, without the need for an instrument, simple operation, low price, and is suitable for primary medical institutions, and is suitable for popularization and self-testing.
Owner:JIANGSU KANGPU BIOMEDICAL TECH CO LTD

Anti-UV engineering plastic and preparation method thereof

The invention belongs to the technical field of high polymer materials, and particularly relates to an anti-UV engineering plastic and a preparation method thereof, and the anti-UV engineering plastic comprises the following raw materials by weight: 88-96 parts of engineering plastic; 8-20 parts of general-purpose plastic; 3-5 parts of an impact modifier; 0.2 to 0.5 part of an anti-UV agent; 0.2 to 1 part of an antioxidant; and 0.1-1 part of a dispersant. The anti-UV engineering plastic material is prepared from the following raw materials: engineering plastic, general plastic, an impact modifier, an anti-UV agent, an antioxidant and a dispersing agent, the engineering plastic is taken as a main body material, auxiliaries such as the general plastic, the impact modifier, the composite antibacterial agent, the antioxidant and the dispersing agent are added for synergistic effect, the anti-UV effect is ensured, the dosage of the anti-UV agent is reduced, and the anti-UV effect is improved. The antibacterial engineering plastic material has the advantages that the light aging of the material can be delayed, and the safety coefficient of the product in the use process is improved.
Owner:QINGDAO GON TECH CO LTD

Methods and Compositions for Treatment of Angiogenic Disorders Using Anti-VEGF Agents

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.
Owner:RGT UNIV OF CALIFORNIA

Anti-insect culture medium and Anti-insect method using the same

The present invention provides an anti-insect culture medium, comprising a shaped medium having a plurality of pores interconnected to each other, and an anti-insect agent evenly dispersed and fixed in the pores; wherein the shaped medium comprises at least one culture medium solid, the anti-insect agent comprises an anti-insect ingredient, and the anti-insect agent is a sustained-release formulation. The anti-insect culture medium of the present invention can provide a long-term and complete anti-insect efficacy to plant roots. The present invention further provides an anti-insect method, which reduces the amount of anti-insect agents and avoids the inconvenience of regular application.
Owner:ROYAL BASE CORP

Plant immune resistance inducer as well as preparation method and application thereof

The invention belongs to but not limited to the technical field of microbial application, and discloses a plant immune resistance inducer as well as a preparation method and application thereof. Comprising an Aava fermentation extract, a surfactant, a defoaming agent, an anti-freezing agent, a thickening agent and a solvent, the Aava fermentation extract is a concentrate of an endophytic alternaria Aava fermentation filtrate, the surfactant is sodium dodecyl sulfate, the defoaming agent is tributyl phosphate, the antifreezing agent and the thickening agent are glycerol, and the solvent is water. The Aava fermentation extract disclosed by the invention is realized by stimulating autoimmunity of kiwi fruit plants, has no any sterilization effect on canker pathogens, and is not easy to generate drug resistance; and the compound has a certain broad spectrum, and has an induced resistance effect on gramineous plant wheat, rosaceae plant apple and solanaceae plant tobacco. When the Aava fermentation extract is used as a plant immune resistance inducer, the defense capability of plants can be improved, and the canker resistance of the plants can be remarkably improved.
Owner:NORTHWEST A & F UNIV

Oral compositions, skin cosmetics, and hair cosmetics

To find compounds derived from natural products excellent in anti-metabolic syndrome action, skin-whitening action, anti-aging action, hair growth action, anti-inflammatory action or liver function-improving action, and provide: an anti-metabolic syndrome agent, a skin-whitening agent, an anti-aging agent, a hair growth agent, an anti-inflammatory agent and a liver function-improving agent that contain the compounds as active ingredients; and oral compositions, skin cosmetics and hair cosmetics comprising the compounds derived from natural products.SOLUTION: Compounds 1 to 3 represented by the general formula (I) in the figure are used.SELECTED DRAWING: None
Owner:MARUZEN PHARMA

Treatment of locally advanced or metastatic urothelium cancer with erdatinib

PendingCN121263186AOrganic active ingredientsAntineoplastic agentsOncologyMetastatic Urothelial Carcinoma
The present invention relates to the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in a patient suffering from FGFR altered mUC and having disease progression during or after one or more prior treatments comprising a checkpoint inhibitor, in particular an anti-PD-(L) 1 agent, with erdatinib.
Owner:JANSSEN PHARMA NV

Hair care composition

A hair care composition is disclosed comprising an anti-dandruff agent selected from piroctone olamine, selenium sulfide and mixtures thereof and a copolymer comprising acrylamidopropyltrimonium chloride, wherein the weight ratio of the amount of the copolymer to the amount of the anti-dandruff agent is in the range of from 1:5 to 1:1.
Owner:CONOPCO INC